• Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Vectura Group PLC

+ Add to Watchlist

VEC:LN

138.750 GBp 5.500 3.81%

As of 11:35:19 ET on 07/10/2014.

Snapshot for Vectura Group PLC (VEC)

Open: 143.750 Day's Range: 137.500 - 144.000 Volume: 611,431
Previous Close: 144.250 52wk Range: 76.250 - 171.500 1-Yr Rtn: +75.63%

Stock Chart for VEC

No chart data available.
  • VEC:LN 138.750
  • 1D
  • 1M
  • 1Y
144.250
Interactive VEC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VEC

Current P/E Ratio (ttm) -
Estimated P/E(03/2015) 693.7500
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.0069
Est. EPS (GBP) (03/2015) 0.0020
Est. PEG Ratio -
Market Cap (M GBP) 557.31
Shares Outstanding (M) 401.66
30 Day Average Volume 802,975
Price/Book (mrq) 3.4177
Price/Sale (ttm) 12.8456
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/18/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VEC

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for VEC

Vectura Group PLC develops inhaled therapies for the treatment of respiratory diseases. The Company's main products are used to treat asthma and chronic obstructive pulmonary disease. Vectura also develops products for lung pathologies and non-respiratory diseases.

Christopher Paul Blackwell "Chris"CEO/Executive DirectorPaul OliverCFO/Secretary
Trevor Michael PhillipsPresident:US Ops/COOTimothy Wright "Tim"Director:Commercial
More Company Profile & Key Executives for VEC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil